Shanghai Pharmaceuticals Holding Co. Ltd.SSE: 601607

2025 Semi-annual Report

Aug 29, 2025 · Issued by Shanghai Pharmaceuticals Holding Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Aug 29, 2025

On 6ix: 6ix.com/news/2025-semi-annual-report-531

2025 Semi-annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix

Earlier from Shanghai Pharmaceuticals

Announcement on Obtaining Philippine Drug Registration Certificate for Oxytocin Injection and Octreotide Acetate InjectionAug 23, 2025
Announcement on the Receipt of Clinical Trial Approval Notice for a New Indication of B019Jul 30, 2025
Announcement on Salbutamol Sulfate Injection Passing Generic Drug Consistency EvaluationJul 29, 2025
Announcement on Acquisition of 10% Equity of SIIC Finance Co., Ltd. and Related Party TransactionsJul 26, 2025
Shanghai Pharmaceuticals Holding: The Fortune 500 company Shanghai Pharmaceuticals enters the dental equipment market by acquiring Finnish dental equipment company Fimet Oy and its operations in Finland and ChinaJul 6, 2021

Later from Shanghai Pharmaceuticals

Announcement on Verapamil Hydrochloride Injection Passing Generic Drug Consistency EvaluationSep 2, 2025
Announcement on Diprophylline Injection Passing Generic Drug Consistency EvaluationSep 5, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Aripiprazole TabletsSep 13, 2025
Announcement on Shareholding Increase Plan for the Controlling ShareholderSep 16, 2025
Announcement on Nicorandil Tablet Passing Generic Drug Consistency EvaluationSep 19, 2025

All Shanghai Pharmaceuticals news releases

Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.

Follow Shanghai Pharmaceuticals